A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity Reaction.

Background: Oxaliplatin hypersensitivity reactions (HSRs) are immunoglobulin E (IgE)-mediated and prevent maximum benefit from this drug. This study was designed to determine whether oxaliplatin HSRs could be prevented or reduced with omalizumab (Xolair), an anti-IgE antibody.

Patients/methods: This was a single-arm prospective pilot study.